利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

59 条记录 (耗时 0.03 秒)

    ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE
    41.
    发明申请
    ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE 审中-公开
    IFNG甲基化在炎症性皮肤病中的作用

    公开(公告)号：US20140018448A1

    公开(公告)日：2014-01-16

    申请号：US14007400

    申请日：2012-03-26

    申请人： Rebecca Gonsky ,  Richard Deem ,  Stephan R. Targan

    发明人： Rebecca Gonsky ,  Richard Deem ,  Stephan R. Targan

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/158

    摘要： The invention relates to method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation. In one embodiment, the present invention provides a method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject, and diagnosing susceptibility to inflammatory bowel disease based on the presence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject. In another embodiment, the IBD is ulcerative colitis.

    摘要翻译： 本发明涉及通过从个体获得样品来诊断个体对炎症性肠病（IBD）的易感性的方法，测定样品以确定一种或多种风险遗传变异体的存在或不存在和/或IFNG DNA的增加 甲基化。 在一个实施方案中，本发明提供了通过从个体获得样品来诊断个体中对炎症性肠病（IBD）易感性的方法，测定样品以确定是否存在一种或多种风险遗传变体和/或 相对于正常受试者，IFNG DNA甲基化的增加，以及基于一种或多种风险遗传变异体的存在和/或IFNG DNA甲基化相对于正常受试者的增加诊断对炎症性肠病的易感性。 在另一个实施方案中，IBD是溃疡性结肠炎。

    METHODS FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE
    42.
    发明申请
    METHODS FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE 审中-公开
    CROHN病的诊断和治疗方法

    公开(公告)号：US20100021455A1

    公开(公告)日：2010-01-28

    申请号：US11720785

    申请日：2005-12-08

    申请人： Stephan R. Targan ,  Carol J. Landers

    发明人： Stephan R. Targan ,  Carol J. Landers

    IPC分类号： A61K39/395 ,  G01N33/00 ,  C12Q1/68 ,  G01N33/68 ,  G01N33/53 ,  A61K35/74 ,  A61P1/00 ,  G01N27/26

    CPC分类号： G01N33/6854 ,  G01N33/6893 ,  G01N2800/065 ,  Y10T436/143333

    摘要： The inventors have discovered an elevated serum response to CBir1 flagellin in Crohn's disease patients. The present invention relates to methods for diagnosis and treatment of Crohn's disease and/or subtypes of Crohn's disease. Diagnosis is accomplished by determining the presence of the anti-CBir1 expression or determining the presence of anti-CBir1 expression and detection of the presence of pANCA. Treatment methods include antigen-directed therapy targeting CBir1 flagellin and manipulating the bacteria in the colon and/or small intestine.

    摘要翻译： 本发明人已经发现克罗恩病患者对CBir1鞭毛蛋白的血清反应升高。 本发明涉及克罗恩病和/或克罗恩病亚型的诊断和治疗方法。 通过确定抗CBIR1表达的存在或确定抗CBir1表达的存在和检测pANCA的存在来实现诊断。 治疗方法包括靶向CBir1鞭毛蛋白的抗原定向治疗和操纵结肠和/或小肠中的细菌。

    ENHANCED T CELL RECEPTOR-MEDIATED TUMOR NECROSIS FACTOR SUPERFAMILY AND CHEMOKINE MRNA EXPRESSION IN PERIPHERAL BLOOD LEUKOCYTES IN PATIENTS WITH CROHN'S DISEASE
    44.
    发明申请
    ENHANCED T CELL RECEPTOR-MEDIATED TUMOR NECROSIS FACTOR SUPERFAMILY AND CHEMOKINE MRNA EXPRESSION IN PERIPHERAL BLOOD LEUKOCYTES IN PATIENTS WITH CROHN'S DISEASE 有权
    增强T细胞受体介导的肿瘤坏死因子超家族和CHEMOKINE在外周血白细胞介素的表达与患有慢性疾病的患者

    公开(公告)号：US20090253133A1

    公开(公告)日：2009-10-08

    申请号：US12296425

    申请日：2007-04-05

    申请人： Masato Mitsuhashi ,  Stephan R. Targan

    发明人： Masato Mitsuhashi ,  Stephan R. Targan

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158

    摘要： A method is disclosed for determining whether a human having Crohn's disease is likely to respond to a therapy targeting a TNFSF member or a cytokine by measuring the level of certain mRNAs in response to a stimulus. A method of evaluating the effectiveness of a Crohn's disease therapy in a human is also disclosed. Furthermore, a method of screening compounds for use in the treatment of Crohn's disease is disclosed. A method of monitoring the disease state over time in Crohn's disease patients is also disclosed.

    摘要翻译： 公开了一种用于通过测量响应于刺激的某些mRNA的水平来确定克罗恩病患者是否可能对靶向TNFSF成员或细胞因子的治疗作出反应的方法。 还公开了评估人类克罗恩病治疗有效性的方法。 此外，公开了一种筛选用于治疗克罗恩病的化合物的方法。 还公开了一种在克罗恩病患者中随时间监测疾病状态的方法。

    Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
    50.
    发明授权
    Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1 失效
    使用组蛋白H1诊断，预防和治疗溃疡性结肠炎及其临床亚型

    公开(公告)号：US6074835A

    公开(公告)日：2000-06-13

    申请号：US837058

    申请日：1997-04-11

    申请人： Johnathan Braun ,  Stephan R. Targan ,  Mark Eggena

    发明人： Johnathan Braun ,  Stephan R. Targan ,  Mark Eggena

    IPC分类号： G01N33/68 ,  G01N33/564

    CPC分类号： G01N33/6875 ,  G01N2800/065

    摘要： The present invention provides a method of diagnosing ulcerative colitis (UC) in a subject suspected of having inflammatory bowel disease by by obtaining a sample from the individual; contacting the sample with human histone H1, or pANCA-reactive fragment thereof, under conditions suitable to form a complex of human histone H1, or pANCA-reactive fragment thereof, and antibody to human histone H1; and detecting the presence or absence of the complex, where the presence of the complex indicates that the individual has UC. The invention also provides related methods of diagnosing a perinuclear anti-neutrophil cytoplasmic antibody positive (pANCA-positive) clinical subtype of UC in a patient with UC. In addition, the invention further provides methods of determining susceptibility to UC in an individual. The invention further provides methods of inducing tolerance in a pANCA-positive patient with UC by administering an effective dose of histone H1, or tolerogenic fragment thereof, to the pANCA-positive patient with UC. Compositions of histone H1, or fragment thereof, combined with a tolerogizing molecule also are provided.

    摘要翻译： 本发明提供一种通过从个体获得样品来诊断疑似患有炎症性肠病的受试者的溃疡性结肠炎（UC）的方法; 在适于形成人组蛋白H1或其pANCA反应性片段的复合物和人组蛋白H1的抗体的条件下，将样品与人组蛋白H1或其pANCA反应性片段接触; 并检测复合物的存在或不存在，其中复合物的存在表明个体具有UC。 本发明还提供了在UC患者中诊断UC的核周抗中性粒细胞胞质抗体阳性（pANCA阳性）临床亚型的相关方法。 此外，本发明还提供了确定个体对UC的易感性的方法。 本发明进一步提供了通过向具有UC的pANCA阳性患者施用有效剂量的组蛋白H1或其耐受性片段来诱导具有UC的pANCA阳性患者的耐受性的方法。 还提供组蛋白H1或其片段的组合物与耐受性分子组合。